大会分论坛中，在研讨"推动中医文化走向世界——破解传播痛点，创新国际路径"环节，津药达仁堂集 团品牌与市场中心副总监赵琳珊作了题为《津药达仁堂以品牌焕新助力健康中国：中医药国际化实践与 与前两届论坛相比，本届首次融合"国韵中医药文化产业创新发展峰会"定位，聚焦"中医药健康产业创 新与产业链升级"，实现学术研讨与产业创新双轮驱动，在聚焦中医药传承的基础上，更加强化文化产 业的跨界融合与国际传播，成为本届大会的核心亮点之一。 在关于中医药产业链升级研讨论坛中，津药达仁堂集团首席信息官（CIO）叶辉作了题为《从古法传承 到智能跃迁——达仁堂的AI赋能中医药全链条实践》主题演讲，介绍了达仁堂集团概况、分析了数字 化转型政策与市场趋势，阐述了达仁堂的数字化、AI及数据战略，并展示转型以来的AI实践及数据要 素创新成果。（阎丽梅） 中医文化市集爆品展播环节，对一附院药食面包、《药用植物（三）》特种邮票、南开医院八珍糕、祁 一堂九蒸九晒系列、西青中医院代茶饮、太平药灸巨罐疗法、天津现代医疗大数据有限公司智能设备及 代茶饮、达仁医院古法秋梨膏、南开医院一剂凉茶、艾草保暖袜子十个产品进行集中展播，并精选三款 产品登台进行重点推 ...

Core Insights - The recent strategic moves by Gu Sheng Tang, a leading Chinese traditional medicine chain, include a partnership with 1doc in Singapore, the launch of "National Medicine AI Avatar," and collaboration with financial institution AGP, marking a significant shift from product export to service system export in traditional Chinese medicine (TCM) internationalization [2][3][4]. Group 1: Strategic Partnerships - Gu Sheng Tang's collaboration with 1doc involves a shareholding structure where Gu Sheng Tang holds 70% and is responsible for operations, allowing for deep integration of TCM services within the existing Western medical framework [3][4]. - This partnership enables patients to receive integrated TCM and Western medical treatment within the same healthcare ecosystem, enhancing the overall healthcare management experience [4]. Group 2: Policy Alignment and Market Opportunities - The partnership aligns with Singapore's government policy promoting the integration of TCM and Western medicine, particularly the "Traditional Chinese Medicine Integration Sandbox" plan set to launch in 2025 [4][5]. - Singapore's open market and innovative policies provide a high-standard international testing ground for Gu Sheng Tang's TCM practices, which could be replicated in Southeast Asia and globally [5][9]. Group 3: Technological Advancements - The launch of the "National Medicine AI Avatar" aims to standardize and replicate TCM practices, providing an intelligent learning platform for overseas TCM practitioners [7][8]. - This AI system is designed to alleviate the shortage of qualified TCM practitioners abroad and assist in developing precise treatment plans, thereby establishing high-quality TCM service standards in international markets [7][8]. Group 4: Capital Support - Gu Sheng Tang's strategic partnership with AGP will provide direct investment to support its internationalization strategy and AI technology development, enhancing its global healthcare footprint [8]. - The investment from AGP, a spin-off from Singapore's state strategic fund, not only offers financial backing but also access to a network of healthcare resources and insights into international market regulations [8]. Group 5: Industry Implications - The developments signify a paradigm shift in TCM internationalization from isolated cultural exports to a systematic and integrated approach within local healthcare ecosystems [9]. - Singapore serves as an ideal testing ground for this new model, which, if successful, could lead to rapid replication in other international markets [9].